



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Sujatha Karoor, et al.)
Serial No.: 09/990,673)
Filed: November 13, 2001)
Title: METHOD AND COMPOSITION FOR) Group Art Unit: 3763
REMOVING UREMIC TOXINS IN DIALYSIS) Examiner: Unknown
PROCESSES)
Confirmation No.: 2485
Attorney)
Docket No.: DI-5666)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir/Madam:

In accordance with 37 C.F.R. §1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO/SB/08A and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is given to charge the amount of any such fee to Deposit Account No. 02-1444. A duplicate of this letter is enclosed for accounting purposes.

Also, please acknowledge receipt by stamping the enclosed self-addressed, stamped postcard that identifies the documents filed herewith.

Respectfully submitted,

Joseph P. Reagen
Attorney for Applicant
Registration No. 35,332

Date: January 17, 2003
Baxter Healthcare Corporation
One Baxter Parkway, DF3-3E
Deerfield, Illinois 60015
(847) 948-3315



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

RECEIVED

JAN 30 2003

TECHNOLOGY CENTER R3700

APPLICANTS: Sujatha Karoor, et al.

GROUP ART UNIT: 3763

SERIAL NO.: 09/990,673

EXAMINER: Unknown

FILING DATE: November 13, 2001

ATTY. DOCKET NO.: DI-5666

HONORABLE ASST. COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

CONFIRMATION NO: 2485

Dear Sir/Madam:

Submitted herewith is an Information Disclosure Statement for consideration in the above-identified application. This Information Disclosure Statement is submitted:

☒ Within 3 months (1) of filing date of a national application; (2) of date of entry of the national stage as set forth in 37 CFR §1.491 in an international application; or (3) before the mailing date of a first Office Action on the merits, whichever occurs last. (No fee is required.)

☐ After the mailing date of a first Office Action but before (1) mailing of a final action under 37 CFR §1.311, whichever occurs first.

☐ Please charge payment for the fee set forth in 37 CFR §1.17(i)(1) to Deposit Account No. 02-1444.

☒ The certification specified in 37 CFR §1.97(e) is made below. (No fee is required.)

☐ After the mailing of (1) a final action under 37 CFR §1.113; or (2) a notice of allowance under 37 CFR §1.311 whichever occurs first, but before payment of the issue fee. The certification specified in 37 CFR §1.97(e) is made below. The Commissioner hereby is petitioned to consider the Information Disclosure Statement accompanying the submission.


☒ The undersigned counsel for applicant(s) hereby certifies each item of information identified in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ The undersigned counsel for applicant(s) hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the statement.

☒ The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Account No. 02-1444. *A duplicate copy of this sheet is enclosed for this purpose.*

Very respectfully,

Baxter Healthcare Corporation,



Joseph P. Reagen

Reg. No. 35,332

When phoning re this application,
please call (847) 948-3315

Baxter Healthcare Corporation
One Baxter Parkway, DF3-3E
Deerfield, Illinois 60015
Telephone: (847) 948-3866

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Asst. Commissioner for Patents, Washington, DC on January 17, 2003


Joseph P. Reagen

Reg. No. 35,332

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	09/990,673
Filing Date	13 November 2001
First Named Inventor	Sujatha Karoor
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	DI-5666

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.